Shandong Aonai Biopharmaceutical Co., Ltd., a leading pet probiotics manufacturer and pet supplement supplier based in Linyi City, Shandong Province, China, has been officially designated as a drafting workgroup unit of the group standard T/CAQI 362-2023 General Rules for Probiotics in Pet Food, issued by the China Association for Quality Inspection (CAQI) on January 10, 2024. The designation recognizes the company's in-depth technical participation in the development of China's first-generation group standard governing probiotics in pet food ― work that directly builds on its proprietary Dr.kalan probiotic technology.
Unlike a general endorsement, designation as a drafting workgroup unit reflects hands-on participation in the technical drafting process. Members of the drafting workgroup contribute to the formulation of the standard's core technical content, including strain selection criteria, viable cell count requirements, stability testing methods, labeling specifications, and quality control procedures.
Shandong Aonai Biopharmaceutical's participation in the T/CAQI 362-2023 drafting workgroup drew on its accumulated expertise in probiotic pet food, including:
Proprietary strain technology: the Dr.kalan compound probiotic's core strains, deposited at the China General Microbiological Culture Collection Center (CGMCC) under deposit numbers 10701, 13044, 17225, and 19824, provided practical reference for the standard's strain quality requirements;
Industrial production experience: the company's standardized production process, characterized by low viable bacteria loss and suitability for large-scale manufacturing, informed the standard's quality control provisions;International perspective: the company's R&D professional holds the U.S. FSPCA PCQI certification for animal food preventive controls, bringing international food safety practices into the domestic standard-setting process.
Group standard T/CAQI 362-2023 General Rules for Probiotics in Pet Food was published on December 15, 2023, and implemented on December 22, 2023. As the first national group standard of its kind, it plays a foundational role in regulating the rapidly growing probiotic pet food market, where global search volumes for dog probiotics and cat probiotics reach tens of thousands of monthly queries.
For pet owners, the standard means clearer quality expectations and safer products. For the industry, it provides a unified technical baseline that separates qualified products from unverified ones. For international buyers, it offers a reference framework for evaluating the quality of probiotic pet food sourced from China.
Within the drafting workgroup, the company contributed to several core technical discussions: how to define strain-specific quality benchmarks, how to set realistic viable count requirements that remain meaningful at the end of shelf life, how to verify stability claims through standardized testing, and how to frame labeling rules that protect both consumers and honest producers. These contributions were shaped by the company's own production reality ― its Dr.kalan probiotic manufacturing line operates under standardized process parameters with low viable bacteria loss, providing a practical reference point for what the industry can and should achieve.
The company's standard-setting participation is backed by internationally verified technology. The Dr.kalan compound probiotic has been granted a Dutch invention patent (No. 4000956, granted July 30, 2026), with the patent confirming four verified advantages over existing products:
1. 35% higher intestinal colonization rate than human-derived strains;
2. 24-month room-temperature shelf life with viable bacteria retention of no less than 80%;
3. More than 50% improvement in intestinal problem resolution under stress conditions;
4. High industrialization feasibility for large-scale, standardized production.These are not marketing claims ― they are the verified technical parameters recorded in an internationally granted patent. For partners building probiotic product lines through OEM/ODM, private label, or bulk supply programs, this combination of standard-setting participation and granted patent protection offers an unusually strong foundation for market differentiation.
Shandong Aonai Biopharmaceutical Co., Ltd. is a science-driven pet health enterprise located in the Wenshui Industrial Park, Pingyi County, Linyi City, Shandong Province, China. The company integrates R&D, production, and sales, with a product portfolio spanning dog joint supplements, dog multivitamins, dental care products, and digestive & probiotic supplements under its Dr.kalan brand. As an experienced pet supplement manufacturer and pet supplement supplier, the company offers flexible OEM/ODM, private label, and custom formula services to brands and distributors worldwide. Its quality assurance system is backed by an FSPCA PCQI-certified R&D team, and the company holds multiple international invention patents and patent applications covering its Dr.kalan compound probiotics and gastric acid-resistant collagen peptides. Committed to "quality first, safety first, technology driven," Shandong Aonai is dedicated to delivering safe, scientific, and premium pet health products to pets and pet parents around the world.
As a drafting workgroup unit of T/CAQI 362-2023, Shandong Aonai Biopharmaceutical remains committed to advancing probiotic science, upholding the standards it helped create, and delivering trusted gut health solutions to pets and pet parents worldwide ― while continuing to support the evolution of China's pet food standardization system.
EN
